Study on the mechanism of Bifidobacterium improving the prognosis of hyperbilirubinemia nervous system

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400091431

Enrollment

Unknown

Registered

2024-10-28

Start date

2024-10-31

Completion date

Unknown

Last updated

2024-11-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperbilirubinemia

Interventions

Experimental group:Oral probiotics

Control group:None

Eligibility

Sex/Gender

All

Age

No minimum to 2 Years

Inclusion criteria

Inclusion criteria: Children with severe hypercholesterolemia were enrolled according to the American Academy of Pediatrics' Guidelines for Diagnosis and Treatment of Neonatal Jaundice.

Exclusion criteria

Exclusion criteria: Congenital malformation, surgical diseases; Chromosome abnormality, congenital metabolic abnormality; Neonatal asphyxia, septicemia or suspected septicemia; ABO hemolysis or RH hemolysis requires blood exchange, glucose -6- phosphate dehydrogenase deficiency.

Design outcomes

Primary

Measure	Time frame
Serum bilirubin;Nerve axon guiding factor;	—

Secondary

Measure	Time frame
Intestinal flora;Height;Weight;Head circumference;	—

Countries

China

Contacts

Public ContactZhang Jinping

Shanghai Sixth People's Hospital

zhang-jin-ping@163.com+86 180 1757 9729

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026